Tadasuke Shimokawaji
Yokohama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903.
Journal: ESMO open
Published: November 27, 2020
Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 26, 2020
Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor.
Journal: International journal of cancer
Published: July 08, 2018
Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas® EGFR mutation test.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 30, 2016
Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells.
Journal: Antimicrobial agents and chemotherapy
Published: June 21, 2016
Relapse of both small cell lung cancer and Lambert-Eaton myasthenic syndrome after a 13-year disease-free survival period.
Journal: Chinese journal of cancer
Published: November 19, 2015
HO-1 inhibits IL-13-induced goblet cell hyperplasia associated with CLCA1 suppression in normal human bronchial epithelial cells.
Journal: International immunopharmacology
Published: June 22, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026